Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

News Daily News

CMS Greenlights Reimbursement for Renal Denervation Systems

L.A. McKeown

October 29, 2025

News Daily News

Take Heed of Sex Differences in Peripheral Vascular Disease: AHA

Michael O'Riordan

March 13, 2025

News Daily News

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

L.A. McKeown

December 12, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

L.A. McKeown

August 23, 2023

News Daily News

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

L.A. McKeown

August 18, 2023

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Industry News

IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly

January 22, 2022

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

Advertisement

CMS Greenlights Reimbursement for Renal Denervation Systems

Take Heed of Sex Differences in Peripheral Vascular Disease: AHA

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

September 2024 Dispatch for the CV Team

August 2024 Dispatch for the CV Team

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Top Endovascular News of 2023

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

BP Reduction With Renal Denervation Still Evident a Decade On

Reduction in BP Drives Treatment Preference for Hypertensive Patients

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

September 2022 News Roundup

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly

December 2021 News Roundup

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content